TACO-BEL-3: a feasibility study and a retrospective audit of diuretics for patients receiving blood transfusion at ten hospitals.
Aditi KhandelwalYulia LinChristine M Cserti-GazdewichMuntadhar Al MoosawiChantal ArmaliDonald ArnoldJeannie CallumKaren L DallasLani LiebermanKaterina PavenskiBenjamin Rioux-MasséNadine ShehataAndrew W ShihJacob PendergrastPublished in: Vox sanguinis (2020)
A large number of transfusion episodes met eligibility criteria. With a 3% incidence of TACO, 50% decrease through the use pre-transfusion furosemide and a target consent rate of 30%, a definitive trial of approximately 3000 patients could be completed within 1 year.